Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Blood (2023) 141 (8): 917–929.

https://doi.org/10.1182/blood.2022016846

Published: 2023

Includes: Supplemental data

Journal Articles

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera

Roland Jäger, Heinz Gisslinger, Elisabeth Fuchs, Edith Bogner, Jelena D. Milosevic Feenstra, Jakob Weinzierl, Fiorella Schischlik, Bettina Gisslinger, Martin Schalling, Michael Zörer, Kurt Krejcy, Christoph Klade, Robert Kralovics

Blood (2021) 137 (3): 387–391.

https://doi.org/10.1182/blood.2020005792

Published: 2021

Includes: Supplemental data

Journal Articles

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Blood (2019) 134 (2): 199–210.

https://doi.org/10.1182/blood.2019000519

Published: 2019

Includes: Supplemental data

Journal Articles

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, MSc, Kurt Krejcy, PhD, Rudolf S. Widmann, PhD BSc, Robert Kralovics, PhD, Maria-Theresa Krauth, MD

Blood (2018) 132 (Supplement 1): 3029.

https://doi.org/10.1182/blood-2018-99-119268

Published: 2018

Journal Articles

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Blood (2018) 132 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2018-99-118584

Published: 2018

Journal Articles

Mutational Landscape of the Transcriptome Offers a Rich Neoantigen Resource for Immunotherapy of Myeloproliferative Neoplasms

Blood (2018) 132 (Supplement 1): 3058.

https://doi.org/10.1182/blood-2018-99-118049

Published: 2018

Journal Articles

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

Blood (2018) 132 (Supplement 1): 4.

https://doi.org/10.1182/blood-2018-99-118348

Published: 2018

Journal Articles

Essential Thrombocythemia Versus Pre-Fibrotic/Early Primary Myelofibrosis: Discrimination By Laboratory and Clinical Data

Martin Schalling, Andreas Gleiss, Bettina Gisslinger, Albert Wölfler, Veronika Buxhofer-Ausch, Georg Jeryczynski, MD, Maria-Theresa Krauth, MD, Ingrid Simonitsch-Klupp, MD, Christine Beham-Schmid, Jurgen Thiele, Heinz Gisslinger

Blood (2017) 130 (Supplement 1): 4201.

https://doi.org/10.1182/blood.V130.Suppl_1.4201.4201

Published: 2017

Journal Articles

Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project

Georg Jeryczynski, MD, Bettina Gisslinger, Martin Schalling, Maria Theresa Krauth, MD, Leonhard Muellauer, MD, Ana-Iris Schiefer, MD, Christoph Kornauth, MD, Ingrid Simonitsch-Klupp, MD, Jürgen Thiele, MD PhD, Heinz Gisslinger

Blood (2016) 128 (22): 4252.

https://doi.org/10.1182/blood.V128.22.4252.4252

Published: 2016

Journal Articles

Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis

Heinz Gisslinger, Martin Schalling, Bettina Gisslinger, Roland Jäger, PhD, Edith Bogner, Ashot S Harutyunyan, PhD, Jelena D Milosevic Feenstra, Nicole C.C. Them, Maria-Theresa Krauth, MD, Leonhard Muellauer, MD, Juergen Thiele, MD PhD, Robert Kralovics

Blood (2016) 128 (22): 1931.

https://doi.org/10.1182/blood.V128.22.1931.1931

Published: 2016

Journal Articles

Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis

Georg Jeryczynski, MD, Albert Woelfler, MD, Bettina Gisslinger, Martin Schalling, Sonja Burgstaller, MD, Veronika Buxhofer-Ausch, Maria Theresa Krauth, MD, Klaus Geissler, MD, Ernst Schlögl, MD, Thamer Sliwa, MD, Ana-Iris Schiefer, MD, Leonhard Muellauer, MD, Ingrid Simonitsch-Klupp, MD, Christine Beham-Schmid, MD, Jürgen Thiele, MDPhD, Heinz Gisslinger

Blood (2016) 128 (22): 1932.

https://doi.org/10.1182/blood.V128.22.1932.1932

Published: 2016

Journal Articles

Monitoring Molecular Response, Minimal Residual Disease and Clonal Structures in Polycythemia Vera Patients Treated with Interferon Alpha

Roland Jäger, Edith Bogner, Kerstin Trenker, Michael Gurbisz, Bettina Gisslinger, Martin Schalling, Faith Hall-Glenn, Nicole C.C. Them, Christoph Klade, Heinz Gisslinger, Gregor Hoermann, Robert Kralovics

Blood (2016) 128 (22): 1944.

https://doi.org/10.1182/blood.V128.22.1944.1944

Published: 2016

Journal Articles

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

Blood (2016) 127 (3): 325–332.

https://doi.org/10.1182/blood-2015-07-661835

Published: 2016

Includes: Supplemental data

Journal Articles

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud

Blood (2015) 126 (23): 1603.

https://doi.org/10.1182/blood.V126.23.1603.1603

Published: 2015

Journal Articles

Whole Exome Sequencing Identifies Novel MPL and JAK2 M utations in Triple Negative Myeloproliferative Neoplasms

Jelena D Milosevic Feenstra, PhD, Harini Nivarthi, PhD, Heinz Gisslinger, MD, Emilie Leroy, Elisa Rumi, MD, Ilyas Chachoua, Klaudia Bagienski, Blanka Kubesova, MSc, Daniela Pietra, PhD, Bettina Gisslinger, Roland Jäger, PhD, Doris Chen, PhD, Tiina Berg, B.Sc., Martin Schalling, MSc, Michael Schuster, PhD, Christoph Bock, PhD, Stefan N. Constantinescu, MD PhD, Mario Cazzola, MD, Robert Kralovics, PhD

Blood (2015) 126 (23): 606.

https://doi.org/10.1182/blood.V126.23.606.606

Published: 2015

Journal Articles

Common Variation at 6q25.3 ( TULP4 ) Influences Risk for Arterial Thrombosis in Myeloproliferative Neoplasms

Roland Jäger, PhD, Ashot S Harutyunyan, PhD, Elisa Rumi, MD, Bettina Gisslinger, Martin Schalling, MSc, Virginia Ferretti, PhD, Daniela Pietra, PhD, Mario Cazzola, MD, Heinz Gisslinger, MD, Robert Kralovics, PhD

Blood (2015) 126 (23): 4088.

https://doi.org/10.1182/blood.V126.23.4088.4088

Published: 2015

Journal Articles

Fusion Gene Detection Using Whole Transcriptome Analysis in Patients with Chronic Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia

Fiorella Schischlik, MSc, Jelena D. Milosevic Feenstra, PhD, Elisa Rumi, MD, Daniela Pietra, PhD, Bettina Gisslinger, Martin Schalling, MSc, Edith Bogner, Heinz Gisslinger, MD, Mario Cazzola, MD, Robert Kralovics, PhD

Blood (2015) 126 (23): 4093.

https://doi.org/10.1182/blood.V126.23.4093.4093

Published: 2015

Journal Articles

Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient

Blood (2015) 126 (23): 4056.

https://doi.org/10.1182/blood.V126.23.4056.4056

Published: 2015

Journal Articles

Long-Term Follow-up in Interferon-Alpha Treated Polycythemia Vera Patients - a Single Center Analysis

Georg Jeryczynski, MD, Bettina Gisslinger, Maria Theresa Krauth, MD, Martin Schalling, MSc, Heinz Gisslinger, MD

Blood (2015) 126 (23): 1608.

https://doi.org/10.1182/blood.V126.23.1608.1608

Published: 2015

Journal Articles

Influence of Platelet and White Blood Cell Counts until Major Thrombosis: Analysis from a Patient Registry in Essential Thrombocythemia

Veronika Buxhofer-Ausch, Michael Steurer, Siegfried Sormann, Ernst Schloegel, Wolfgang Schimetta, Bettina Gisslinger, Reinhard Ruckser, Martin Schalling, MSc, Guenther A. Gastl, MD, Heinz Gisslinger, MD

Blood (2015) 126 (23): 2814.

https://doi.org/10.1182/blood.V126.23.2814.2814

Published: 2015

NARROW

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Mutational Landscape of the Transcriptome Offers a Rich Neoantigen Resource for Immunotherapy of Myeloproliferative Neoplasms

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

Essential Thrombocythemia Versus Pre-Fibrotic/Early Primary Myelofibrosis: Discrimination By Laboratory and Clinical Data

Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project

Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis

Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis

Monitoring Molecular Response, Minimal Residual Disease and Clonal Structures in Polycythemia Vera Patients Treated with Interferon Alpha

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud

Whole Exome Sequencing Identifies Novel MPL and JAK2 M utations in Triple Negative Myeloproliferative Neoplasms

Common Variation at 6q25.3 ( TULP4 ) Influences Risk for Arterial Thrombosis in Myeloproliferative Neoplasms

Fusion Gene Detection Using Whole Transcriptome Analysis in Patients with Chronic Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia

Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient

Long-Term Follow-up in Interferon-Alpha Treated Polycythemia Vera Patients - a Single Center Analysis

Influence of Platelet and White Blood Cell Counts until Major Thrombosis: Analysis from a Patient Registry in Essential Thrombocythemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only